Repligen Corp (RGEN) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2025, Repligen reported revenue of $738.3M, up 16.4% from $634.4M the year before. Net income was $48.9M (a 6.6% net margin), or $0.86 per diluted share. Gross margin was 52.3% and operating margin was 7.5%. Operating activities generated $117.4M of cash, leaving $93.9M of free cash flow. At fiscal year end, Repligen held $2.95B in total assets against $843.6M in total liabilities, including $566.0M of cash and equivalents.
Open the full interactive Repligen financials → Quarterly statements, key ratios, valuation history and price charts.
Repligen Key Stats
| Share Price | $175.42 |
|---|---|
| Market Cap | $9.94B |
| P/E Ratio | 204.0 |
| Revenue YoY Growth | +16.4% |
| 52-Week Range | $102.87 – $194.57 |
| Shares Outstanding | 56.4 million (basic, 2026 Q2) |
Repligen Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $366.3M | $670.5M | $801.5M | $638.8M | $634.4M | $738.3M |
| Cost of Goods Sold | $156.6M | $279.3M | $345.8M | $353.9M | $359.8M | $352.0M |
| Gross Profit | $209.6M | $391.3M | $455.7M | $284.8M | $274.6M | $386.2M |
| Operating Income | $69.8M | $167.2M | $224.7M | $54.6M | -$35.1M | $55.2M |
| Pre-Tax Income | $59.2M | $153.5M | $219.1M | $64.1M | -$27.0M | $62.4M |
| Income Tax | -$709,000 | $25.3M | $33.2M | $22.6M | -$1.5M | $13.5M |
| Net Income | $59.9M | $128.3M | $186.0M | $41.6M | -$25.5M | $48.9M |
| Diluted EPS | $1.11 | $2.24 | $3.24 | $0.74 | -$0.46 | $0.86 |
Repligen Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $188.8M | $197.9M | $194.3M | $204.1M |
| Net Income | $14.9M | $13.3M | $8.3M | $5.0M |
| Diluted EPS | $0.26 | $0.23 | $0.15 | $0.09 |
Repligen Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $717.3M | $603.8M | $523.5M | $751.3M | $757.4M | $566.0M |
| Current Assets | $902.4M | $931.7M | $998.1M | $1.11B | $1.07B | $1.14B |
| Total Assets | $1.90B | $2.36B | $2.52B | $2.82B | $2.83B | $2.95B |
| Current Liabilities | $319.0M | $375.3M | $404.2M | $158.2M | $126.8M | $135.8M |
| Total Long-Term Debt | — | — | — | $579.6M | $525.6M | $542.2M |
| Total Liabilities | $373.7M | $608.3M | $614.0M | $853.2M | $856.9M | $843.6M |
| Shareholders' Equity | $1.53B | $1.75B | $1.91B | $1.97B | $1.97B | $2.11B |
Repligen Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | $62.6M | $119.0M | $172.1M | $113.9M | $175.4M | $117.4M |
| Cash From Investing | -$201.4M | -$221.2M | -$233.2M | -$123.3M | -$86.4M | -$298.5M |
| Cash From Financing | $305.9M | $961,000 | -$13.3M | $249.0M | -$82.9M | -$15.2M |
| Free Cash Flow | $40.2M | $51.9M | $87.2M | $77.7M | $149.7M | $93.9M |
Figures from Repligen's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Repligen financials page for every line item.
Repligen Company Profile
| Ticker | RGEN |
|---|---|
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | Waltham, Massachusetts |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0000730272 |
Frequently Asked Questions
What was Repligen's revenue in fiscal 2025?
Repligen (RGEN) reported revenue of $738.3M for fiscal 2025.
What is Repligen's annual revenue history?
Repligen's annual revenue by fiscal year: 2020: $366.3M; 2021: $670.5M; 2022: $801.5M; 2023: $638.8M; 2024: $634.4M; 2025: $738.3M.
What was Repligen's net income in fiscal 2025?
Repligen reported net income of $48.9M for fiscal 2025.
What was Repligen's earnings per share (EPS) in fiscal 2025?
Repligen's diluted EPS was $0.86 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Repligen generate in fiscal 2025?
Repligen generated $93.9M of free cash flow in fiscal 2025.
What was Repligen's revenue last quarter?
In its most recent reported quarter (2026 Q2), Repligen reported revenue of $204.1M.
How much debt does Repligen have?
Repligen reported $542.2M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Repligen are outstanding?
Repligen reported a weighted average of 56.4 million basic shares outstanding in 2026 Q2.
What is Repligen's market cap?
Based on its latest closing price, Repligen (RGEN) has a market capitalization of about $9.94B.
When does Repligen's fiscal year end?
Repligen's fiscal year end, as registered with the SEC, is December 31.
Where is Repligen headquartered?
Repligen lists its business address in Waltham, Massachusetts in its SEC filings.
Repligen Competitors & Similar Companies
See all 136 Biological Products, (No Diagnostic Substances) companies →